Mind Technology, Inc. shares rise 3.54% intraday after Neurolief's strategic investment and FDA approval anticipation for Proliv™Rx.
ByAinvest
Thursday, Aug 21, 2025 1:22 pm ET1min read
MIND--
Mind Technology, Inc. rose 3.54% intraday, with the company's strategic investment in Neurolief, a pioneering brain stimulation company specializing in non-invasive neuromodulation therapies, marking a significant milestone as Neurolief awaits FDA approval and prepares for the commercial launch of its Proliv™Rx system designed for the treatment of Major Depressive Disorder (MDD). This investment reflects an exciting strategic alignment between the two companies, both dedicated to expanding access to innovative, clinically validated, and non-invasive mental health treatments.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet